ABVX · Abivax SA
$88.01
-2.46% last session
End-of-day data · close of 2026-10-23
Market cap
$8B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
-23.0
Dividend yield
0.0%
Beta
-0.23
Avg volume
1M
Employees
0K
Daily Change %
-2.46%
5 Days Change
2.38%
10 Days Change
4.65%
30 Days Change
-4.14%
60 Days Change
-22.32%
Month to Day Change
-5.12%
Year to Day Change
-33.09%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ABVX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
Barclays
Overweight$148
+68.2% vs priceGoldman Sachs
Buy$155
+76.1% vs priceJefferies
Buy$158
+79.5% vs priceMorgan Stanley
Overweight$132
+50.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Wedbush | Maintains | Neutral | $118 → $96.00 |
| 2026-10-20 | Guggenheim | Reiterates | Buy | $175 |
| 2026-09-22 | Truist Securities | Maintains | Buy | $155 → $151 |
| 2026-09-22 | Wedbush | Maintains | Neutral | $140 → $118 |
| 2026-09-22 | Barclays | Maintains | Overweight | $148 |
| 2026-09-10 | Goldman Sachs | Initiates | Buy | $0.00 → $155 |
| 2026-09-05 | BTIG | Reiterates | Buy | $175 |
| 2026-07-09 | Piper Sandler | Maintains | Overweight | $165 → $175 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 40 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 14.8% below the 50-day MA ($103.30).
- bearish: Price vs 200-day MA: Trading 23.4% below the 200-day MA ($114.87).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+1.00) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($72.50) and high ($145.31).
ABVX Price Chart
Loading chart for ABVX…
Fundamentals
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.